Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer

Pancreatic cancer is a cancer with a poor prognosis and a high mortality rate. The prognosis of surgically resectable pancreatic cancer is better than that of unresectable pancreatic cancer. But the prognosis is still poor enough to report a 2-year disease-free survival rate of 47.0% despite the application of standard treatment. Preoperative chemotherapy or radiotherapy for pancreatic cancer has been performed for a long time, especially for locally advanced pancreatic cancer. However, there are very few studies on the application of preoperative chemotherapy or radiotherapy for borderline re

Trial Details

NCT ID
NCT05679583
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Histologically diagnosed adenocarcinoma of the pancreas
  • Resectable pancreatic cancer at the time of diagnosis
  • Resectable pancreatic cancer refers to cases in which all of the following conditions are met:
  • If the tumor does not reach the superior mesenteric vein or portal vein, or even if it does, it reaches within 180°

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →